Wassila Saiah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wassila Saiah has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Elhadj-Ahmed Koceir
University of Sciences and Technology Houari Boumediene, Algiers, Algeria, Algeria
3 shared publications - Ali Haddam
Diabetology Unit, University Hospital Center, Mohamed Lamine Debaghine, Algiers I-University, Bab El Oued, Algiers 16000, Algeria
2 shared publications - Amel Otmane
Biochemistry and Genetics Laboratory, University Hospital Center, Mohamed Lamine Debaghine, Bab El Oued, Algiers 16000, Algeria
2 shared publications - Hamza Saidi
Bioenergetics and Intermediary Metabolism Team, Laboratory of Biology and Organism Physiology, Biological Sciences Faculty, Nutrition and Pathologies Post Graduate School, HouariBoumediene University of Sciences and Technology (USTHB), Bab Ezzouar, Algiers 16123, Algeria
2 shared publications - Houda Zoubiri
Bioenergetics and Intermediary Metabolism Team, Laboratory of Biology and Organism Physiology, Biological Sciences Faculty, Nutrition and Pathologies Post Graduate School, HouariBoumediene University of Sciences and Technology (USTHB), Bab Ezzouar, Algiers 16123, Algeria
2 shared publications - Mohamed Makrelouf
Biochemistry and Genetics Laboratory, University Hospital Center, Mohamed Lamine Debaghine, Bab El Oued, Algiers 16000, Algeria
2 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (9)
Phytochemical Profiling and Biological Evaluation of Pistacia lentiscus L. grown in Chlef (Algeria): An Integrated In Vitro , In Vivo , and In Silico Study
Pistacia lentiscus L. plays an integral role in Algerian traditional therapy. The aim of this study was to evaluate P. lentiscus methanol extract (PLME) for its potential antihypoxic and antioxidant activity and to characterize its phytochemical profile. Locomotor and exploratory behavior were investigated using the open‐field test (OF). Also, biological activity prediction was performed using the PASS online platform, and molecular docking studies were carried out using AutoDock Vina software. Quantitative investigations revealed high levels of total phenolics (713.952 ± 12.58 mg GAE/g extract) and flavonoids (315.821 ± 2.219 mg QE/g extract). The HPLC‐MS analysis identified phenolic acids and flavonoids. The extract exhibited a dose‐dependent increase in scavenging activity and reducing power. PLME could dose‐dependently enhance the survival time of mice under normobaric hypoxia and after injection of sodium nitrite. PLME significantly decreased the malondialdehyde (MDA) level compared to the control group. Furthermore, PLME increased the number of squares crossed and the number of rearings in the OF test. PLME constituents exhibited favorable binding affinities with the HIF‐1α and drug‐likeness properties. This is the first study to evaluate the antihypoxic efficacy of P. lentiscus L. extract and highlight its significance as a medicinal plant by in vivo and in silico approaches.
- 20 September 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (9)
Open AccessPhytochemical Profiling and Biological Evaluation of Pistacia lentiscus L. grown in Chlef (Algeria): An Integrated In Vitro , In Vivo , and In Silico Study
Pistacia lentiscus L. plays an integral role in Algerian traditional therapy. The aim of this study was to evaluate P. lentiscus methanol extract (PLME) for its potential antihypoxic and antioxidant activity and to characterize its phytochemical profile. Locomotor and exploratory behavior were investigated using the open‐field test (OF). Also, biological activity prediction was performed using the PASS online platform, and molecular docking studies were carried out using AutoDock Vina software. Quantitative investigations revealed high levels of total phenolics (713.952 ± 12.58 mg GAE/g extract) and flavonoids (315.821 ± 2.219 mg QE/g extract). The HPLC‐MS analysis identified phenolic acids and flavonoids. The extract exhibited a dose‐dependent increase in scavenging activity and reducing power. PLME could dose‐dependently enhance the survival time of mice under normobaric hypoxia and after injection of sodium nitrite. PLME significantly decreased the malondialdehyde (MDA) level compared to the control group. Furthermore, PLME increased the number of squares crossed and the number of rearings in the OF test. PLME constituents exhibited favorable binding affinities with the HIF‐1α and drug‐likeness properties. This is the first study to evaluate the antihypoxic efficacy of P. lentiscus L. extract and highlight its significance as a medicinal plant by in vivo and in silico approaches.
- Open Access
- 26 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1218
Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities
The triad association among type 2 diabetes mellitus (T2DM), metabolic associated fatty liver disease (MAFLD), and incretin secretion dysfunction, including GLP-1 (glucagon-like peptide-1) secretion dysfunction, maintains a critical cardiovascular risk and liver-related mortality. The aim of this study is to establish interactions between the GLP-1 plasma levels and metabolic syndrome clusters and adipokines profile (leptin, adiponectin, resistin) and proinflammatory cytokines (TNFα, IL-6, IL1β, IL-17) in diabetic subjects with or without MAFLD. The data revealed that insulin resistance (HOMA-IR) is present in all groups. MAFLD is more common in men than in women. The average FLI score in group IV was ≥70, confirming the diagnosis of MAFLD. The disorder of GLP-1 secretion is more pronounced in women than in men. HOMA-IR is negatively associated with plasma GLP-1 depletion in the MAFLD, T2DM, and MAFLD + T2DM groups. Adiponectin levels are decreased in all groups, as for GLP-1. In contrast, leptin, resistin, TNFα, IL-6, IL-1β, and IL-17 levels show an inverse correlation with GLP-1. GLP-1 accurately reflects metabolic and inflammatory status in subjects with MAFLD, T2DM, and diabetes—steatosis. The applied multivariate linear regression model confirms a highly significant association between MAFLD and GLP-1. It appears that plasma GLP-1 can be considered as biomarker in MAFLD and T2DM related to sex-gender disparities. Longitudinal studies are required to confirm these data.
- 26 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1218
Open AccessPlasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities
The triad association among type 2 diabetes mellitus (T2DM), metabolic associated fatty liver disease (MAFLD), and incretin secretion dysfunction, including GLP-1 (glucagon-like peptide-1) secretion dysfunction, maintains a critical cardiovascular risk and liver-related mortality. The aim of this study is to establish interactions between the GLP-1 plasma levels and metabolic syndrome clusters and adipokines profile (leptin, adiponectin, resistin) and proinflammatory cytokines (TNFα, IL-6, IL1β, IL-17) in diabetic subjects with or without MAFLD. The data revealed that insulin resistance (HOMA-IR) is present in all groups. MAFLD is more common in men than in women. The average FLI score in group IV was ≥70, confirming the diagnosis of MAFLD. The disorder of GLP-1 secretion is more pronounced in women than in men. HOMA-IR is negatively associated with plasma GLP-1 depletion in the MAFLD, T2DM, and MAFLD + T2DM groups. Adiponectin levels are decreased in all groups, as for GLP-1. In contrast, leptin, resistin, TNFα, IL-6, IL-1β, and IL-17 levels show an inverse correlation with GLP-1. GLP-1 accurately reflects metabolic and inflammatory status in subjects with MAFLD, T2DM, and diabetes—steatosis. The applied multivariate linear regression model confirms a highly significant association between MAFLD and GLP-1. It appears that plasma GLP-1 can be considered as biomarker in MAFLD and T2DM related to sex-gender disparities. Longitudinal studies are required to confirm these data.
- Open Access
- 9 December 2025
- Published by MDPI AG in Preprints.org
Adaptative Responses of GLP-1 (Glucagon-Like Peptide-1) Plasma Levels to Adipocytokines Profile in Type 2 Diabetic Patients With or Without Metabolic Associated Fatty Liver Disease (MAFLD)
The triad association between Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MAFLD) and incretin secretion dysfunction, including GLP-1 (Glucagon-Like Peptide-1) maintains a critical cardiovascular risk and liver-related mortality. The aim of this study is to establish interactions between the GLP-1 plasma levels and metabolic syndrome clusters and adipokines profile (leptin, adiponectin, resistin) and proinflammatory cytokines (TNFα, IL-6, IL1β, IL-17) in diabetic subjects with or without MAFLD. The data revealed that insulin resistance (Homa-IR) is present in all groups. Homa-IR is negatively associated with plasma GLP-1 depletion in the MAFLD, T2DM and MAFLD + T2DM groups. Adiponectin levels are decreased in all groups as for GLP-1. At the opposite, leptin, resistin, TNFα, IL-6, IL1β and IL-17 levels show an inverse correlation with GLP-1. It appears that plasma GLP-1 can be considered as a transition and evolution biomarker in MAFLD and T2DM. GLP-1 accurately reflects metabolic and inflammatory status, both in subjects with MAFLD only or with T2DM only, before the Diabetes - Steatosis stage.
- 9 December 2025
- Published by MDPI AG in Preprints.org
Open AccessAdaptative Responses of GLP-1 (Glucagon-Like Peptide-1) Plasma Levels to Adipocytokines Profile in Type 2 Diabetic Patients With or Without Metabolic Associated Fatty Liver Disease (MAFLD)
The triad association between Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MAFLD) and incretin secretion dysfunction, including GLP-1 (Glucagon-Like Peptide-1) maintains a critical cardiovascular risk and liver-related mortality. The aim of this study is to establish interactions between the GLP-1 plasma levels and metabolic syndrome clusters and adipokines profile (leptin, adiponectin, resistin) and proinflammatory cytokines (TNFα, IL-6, IL1β, IL-17) in diabetic subjects with or without MAFLD. The data revealed that insulin resistance (Homa-IR) is present in all groups. Homa-IR is negatively associated with plasma GLP-1 depletion in the MAFLD, T2DM and MAFLD + T2DM groups. Adiponectin levels are decreased in all groups as for GLP-1. At the opposite, leptin, resistin, TNFα, IL-6, IL1β and IL-17 levels show an inverse correlation with GLP-1. It appears that plasma GLP-1 can be considered as a transition and evolution biomarker in MAFLD and T2DM. GLP-1 accurately reflects metabolic and inflammatory status, both in subjects with MAFLD only or with T2DM only, before the Diabetes - Steatosis stage.